155 related articles for article (PubMed ID: 19958131)
1. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.
Pandey RS; Dixit VK
J Drug Target; 2010 May; 18(4):282-91. PubMed ID: 19958131
[TBL] [Abstract][Full Text] [Related]
2. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
3. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.
Jain S; Singh P; Mishra V; Vyas SP
Immunol Lett; 2005 Oct; 101(1):41-9. PubMed ID: 15869802
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
5. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Khatri K; Goyal AK; Gupta PN; Mishra N; Vyas SP
Int J Pharm; 2008 Apr; 354(1-2):235-41. PubMed ID: 18182259
[TBL] [Abstract][Full Text] [Related]
6. Cationic transfersomes based topical genetic vaccine against hepatitis B.
Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ISCOMs for immunization against hepatitis B.
Pandey RS; Dixit VK
Curr Pharm Biotechnol; 2009 Nov; 10(7):709-16. PubMed ID: 19751176
[TBL] [Abstract][Full Text] [Related]
8. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
9. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
10. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.
Saini V; Jain V; Sudheesh MS; Jaganathan KS; Murthy PK; Kohli DV
Int J Pharm; 2011 Apr; 408(1-2):50-7. PubMed ID: 21291968
[TBL] [Abstract][Full Text] [Related]
11. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
Shukla A; Katare OP; Singh B; Vyas SP
Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
[TBL] [Abstract][Full Text] [Related]
12. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes.
Mishra D; Mishra PK; Dubey V; Nahar M; Dabadghao S; Jain NK
Eur J Pharm Sci; 2008 Apr; 33(4-5):424-33. PubMed ID: 18359615
[TBL] [Abstract][Full Text] [Related]
13. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
Thomas C; Gupta V; Ahsan F
Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
[TBL] [Abstract][Full Text] [Related]
14. Current status and potential application of ISCOMs in veterinary medicine.
Morein B; Hu KF; Abusugra I
Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
[TBL] [Abstract][Full Text] [Related]
15. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
Aguila A; Donachie AM; Peyre M; McSharry CP; Sesardic D; Mowat AM
Vaccine; 2006 Jun; 24(24):5201-10. PubMed ID: 16650917
[TBL] [Abstract][Full Text] [Related]
16. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization.
Gupta PN; Vyas SP
Colloids Surf B Biointerfaces; 2011 Jan; 82(1):118-25. PubMed ID: 20843665
[TBL] [Abstract][Full Text] [Related]
17. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
Pawar D; Jaganathan KS
Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
[TBL] [Abstract][Full Text] [Related]
18. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
McCluskie MJ; Davis HL
J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
[TBL] [Abstract][Full Text] [Related]
20. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen.
Tiwari S; Verma SK; Agrawal GP; Vyas SP
Int J Pharm; 2011 Jul; 413(1-2):211-9. PubMed ID: 21540094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
